Protein glycosylation in infectious disease pathobiology and treatment

David J Vigerust

doi:10.2478/s11535-011-0050-8

. 2011 Aug 10;6(5):802. doi: 10.2478/s11535-011-0050-8

Protein glycosylation in infectious disease pathobiology and treatment

David J Vigerust ^1,^2,^✉

PMCID: PMC7088636 PMID: 32215117

Abstract

A host of bacteria and viruses are dependent on O-linked and N-linked glycosylation to perform vital biological functions. Pathogens often have integral proteins that participate in host-cell interactions such as receptor binding and fusion with host membrane. Fusion proteins from a broad range of disparate viruses, such as paramyxovirus, HIV, ebola, and the influenza viruses share a variety of common features that are augmented by glycosylation. Each of these viruses contain multiple glycosylation sites that must be processed and modified by the host post-translational machinery to be fusogenically active. In most viruses, glycosylation plays a role in biogenesis, stability, antigenicity and infectivity. In bacteria, glycosylation events play an important role in the formation of flagellin and pili and are vitally important to adherence, attachment, infectivity and immune evasion. With the importance of glycosylation to pathogen survival, it is clear that a better understanding of the processes is needed to understand the pathogen requirement for glycosylation and to capitalize on this requirement for the development of novel therapeutics.

Keywords: Virus, Bacteria, Glycosylation, Infectious disease

References

[1].Witze E.S., Old W.M., Resing K.A., Ahn N.G. Mapping protein post-translational modifications with mass spectrometry. Nat. Methods. 2007;4:798–806. doi: 10.1038/nmeth1100. [DOI] [PubMed] [Google Scholar]
[2].Spiro R.G. Protein glycosylation: nature, distribution, enzymatic formation, and disease implications of glycopeptide bonds. Glycobiology. 2002;12:43R–56R. doi: 10.1093/glycob/12.4.43R. [DOI] [PubMed] [Google Scholar]
[3].Stepper J., Shastri S., Loo T.S., Preston J.C., Novak P., Man P., et al., Cysteine S-glycosylation, a new post-translational modification found in glycopeptide bacteriocins, FEBS letters, 585, 645–650 [DOI] [PubMed]
[4].Furmanek A., Hofsteenge J. Protein C-mannosylation: facts and questions. Acta Biochim. Polon. 2000;47:781–789. [PubMed] [Google Scholar]
[5].Falzarano D., Krokhin O., Van Domselaar G., Wolf K., Seebach J., Schnittler H.J., et al. Ebola sGP—the first viral glycoprotein shown to be C-mannosylated. Virology. 2007;368:83–90. doi: 10.1016/j.virol.2007.06.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
[6].Hartmann S., Hofsteenge J. Properdin, the positive regulator of complement, is highly C-mannosylated. J. Biol. Chem. 2000;275:28569–72854. doi: 10.1074/jbc.M001732200. [DOI] [PubMed] [Google Scholar]
[7].Ristl R., Steiner K., Zarschler K., Zayni S., Messner P., Schaffer C., The s-layer glycome-adding to the sugar coat of bacteria, Int. J. Microbiol., 2011, pi 127870 [DOI] [PMC free article] [PubMed]
[8].Apweiler R., Hermjakob H., Sharon N. On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database. Biochim. Biophys. Acta. 1999;1473:4–8. doi: 10.1016/s0304-4165(99)00165-8. [DOI] [PubMed] [Google Scholar]
[9].Messner P. Prokaryotic glycoproteins: unexplored but important. J. Bacteriol. 2004;186:2517–2519. doi: 10.1128/JB.186.9.2517-2519.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
[10].Weerapana E., Imperiali B. Asparagine-linked protein glycosylation: from eukaryotic to prokaryotic systems. Glycobiology. 2006;16:91R–101R. doi: 10.1093/glycob/cwj099. [DOI] [PubMed] [Google Scholar]
[11].Neuberger A. Carbohydrates in protein: The carbohydrate component of crystalline egg albumin. Biochem. J. 1938;32:1435–1451. doi: 10.1042/bj0321435. [DOI] [PMC free article] [PubMed] [Google Scholar]
[12].Sleytr U. B., Thorne K. J. Chemical characterization of the regularly arranged surface layers of Clostridium thermosaccharolyticum and Clostridium thermohydrosulfuricum. J Bacteriol. 1976;126:377–83. doi: 10.1128/jb.126.1.377-383.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
[13].Sleytr U.B. Heterologous reattachment of regular arrays of glycoproteins on bacterial surfaces. Nature. 1975;257:400–402. doi: 10.1038/257400a0. [DOI] [PubMed] [Google Scholar]
[14].Szymanski C.M., Logan S.M., Linton D., Wren B.W. Campylobacter—a tale of two protein glycosylation systems. Trends Microbiol. 2003;11:233–238. doi: 10.1016/S0966-842X(03)00079-9. [DOI] [PubMed] [Google Scholar]
[15].Wacker M., Linton D., Hitchen P.G., Nita-Lazar M., Haslam S.M., North S.J., et al. N-linked glycosylation in Campylobacter jejuni and its functional transfer into E. coli. Science. 2002;298:1790–1793. doi: 10.1126/science.298.5599.1790. [DOI] [PubMed] [Google Scholar]
[16].Abu-Qarn M., Eichler J. Protein N-glycosylation in Archaea: defining Haloferax volcanii genes involved in S-layer glycoprotein glycosylation. Mol. Microbiol. 2006;61:511–525. doi: 10.1111/j.1365-2958.2006.05252.x. [DOI] [PubMed] [Google Scholar]
[17].Logan S.M. Flagellar glycosylation — a new component of the motility repertoire? Microbiology. 2006;152:1249–1262. doi: 10.1099/mic.0.28735-0. [DOI] [PubMed] [Google Scholar]
[18].Castric P. pilO, a gene required for glycosylation of Pseudomonas aeruginosa 1244 pilin. Microbiology. 1995;141:1247–1254. doi: 10.1099/13500872-141-5-1247. [DOI] [PubMed] [Google Scholar]
[19].Fletcher C.M., Coyne M.J., Villa O.F., Chatzidaki-Livanis M., Comstock L.E. A general O-glycosylation system important to the physiology of a major human intestinal symbiont. Cell. 2009;137:321–331. doi: 10.1016/j.cell.2009.02.041. [DOI] [PMC free article] [PubMed] [Google Scholar]
[20].Coyne M.J., Reinap B., Lee M.M., Comstock L.E. Human symbionts use a host-like pathway for surface fucosylation. Science. 2005;307:1778–1781. doi: 10.1126/science.1106469. [DOI] [PubMed] [Google Scholar]
[21].Power P.M., Seib K.L., Jennings M.P. Pilin glycosylation in Neisseria meningitidis occurs by a similar pathway to wzy-dependent O-antigen biosynthesis in Escherichia coli. Biochem. Biophys. Res. Commun. 2006;347:904–908. doi: 10.1016/j.bbrc.2006.06.182. [DOI] [PubMed] [Google Scholar]
[22].Stimson E., Virji M., Makepeace K., Dell A., Morris H., Payne G., et al. Meningococcal pilin: a glycoprotein substituted with digalactosyl 2,4-diacetamido-2,4,6-trideoxyhexose. Mol. Microbiol. 1995;17:1201–1214. doi: 10.1111/j.1365-2958.1995.mmi_17061201.x. [DOI] [PubMed] [Google Scholar]
[23].Virji M. Post-translational modifications of meningococcal pili. Identification of common substituents: glycans and alpha-glycerophosphate—a review. Gene. 1997;192:141–147. doi: 10.1016/S0378-1119(97)00082-6. [DOI] [PubMed] [Google Scholar]
[24].Hegge F.T., Hitchen P.G., Aas F.E., Kristiansen H., Lovold C., Egge-Jacobsen W. Unique modifications with phosphocholine and phosphoethanolamine define alternate antigenic forms of Neisseria gonorrhoeae type IV pili. Proc. Natl. Acad. Sci. USA. 2004;101:10798–107803. doi: 10.1073/pnas.0402397101. [DOI] [PMC free article] [PubMed] [Google Scholar]
[25].Castric P., Cassels F.J., Carlson R.W. Structural characterization of the Pseudomonas aeruginosa 1244 pilin glycan. J. Biol. Chem. 2001;276:26479–26485. doi: 10.1074/jbc.M102685200. [DOI] [PubMed] [Google Scholar]
[26].Schirm M., Soo E.C., Aubry A.J., Austin J., Thibault P., Logan S.M. Structural, genetic and functional characterization of the flagellin glycosylation process in Helicobacter pylori. Mol. Microbiol. 2003;48:1579–1592. doi: 10.1046/j.1365-2958.2003.03527.x. [DOI] [PubMed] [Google Scholar]
[27].McNally D.J., Aubry A.J., Hui J.P., Khieu N.H., Whitfield D., Ewing C.P., et al. Targeted metabolomics analysis of Campylobacter coli VC167 reveals legionaminic acid derivatives as novel flagellar glycans. J. Biol. Chem. 2007;282:14463–14475. doi: 10.1074/jbc.M611027200. [DOI] [PubMed] [Google Scholar]
[28].Thibault P., Logan S.M., Kelly J.F., Brisson J.R., Ewing C.P., Trust T.J., et al. Identification of the carbohydrate moieties and glycosylation motifs in Campylobacter jejuni flagellin. J. Biol. Chem. 2001;276:34862–34870. doi: 10.1074/jbc.M104529200. [DOI] [PubMed] [Google Scholar]
[29].Sambri V., Stefanelli C., Cevenini R. Detection of glycoproteins in Borrelia burgdorferi. Arch. Microbiol. 1992;157:205–208. doi: 10.1007/BF00245150. [DOI] [PubMed] [Google Scholar]
[30].Swanson A.F., Kuo C.C. Binding of the glycan of the major outer membrane protein of Chlamydia trachomatis to HeLa cells. Infect. Immun. 1994;62:24–28. doi: 10.1128/iai.62.1.24-28.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
[31].Swanson A.F., Kuo C.C. The characterization of lectin-binding proteins of Chlamydia trachomatis as glycoproteins. Microb. Pathog. 1991;10:465–473. doi: 10.1016/0882-4010(91)90112-N. [DOI] [PubMed] [Google Scholar]
[32].Swanson A.F., Kuo C.C. Evidence that the major outer membrane protein of Chlamydia trachomatis is glycosylated. Infect. Immun. 1991;59:2120–2125. doi: 10.1128/iai.59.6.2120-2125.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
[33].Lindenthal C., Elsinghorst E.A. Enterotoxigenic Escherichia coli TibA glycoprotein adheres to human intestine epithelial cells. Infect. Immun. 2001;69:52–57. doi: 10.1128/IAI.69.1.52-57.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
[34].Lindenthal C., Elsinghorst E.A. Identification of a glycoprotein produced by enterotoxigenic Escherichia coli. Infect. Immun. 1999;67:4084–4091. doi: 10.1128/iai.67.8.4084-4091.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
[35].Espitia C., Mancilla R. Identification, isolation and partial characterization of Mycobacterium tuberculosis glycoprotein antigens. Clin. Exp. Immunol. 1989;77:378–383. [PMC free article] [PubMed] [Google Scholar]
[36].Mondotte J.A., Lozach P.Y., Amara A., Gamarnik A.V. Essential role of dengue virus envelope protein N glycosylation at asparagine-67 during viral propagation. J. Virol. 2007;81:7136–7148. doi: 10.1128/JVI.00116-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
[37].Korber B., Gaschen B., Yusim K., Thakallapally R., Kesmir C., Detours V. Evolutionary and immunological implications of contemporary HIV-1 variation. Br. Med. Bull. 2001;58:19–42. doi: 10.1093/bmb/58.1.19. [DOI] [PubMed] [Google Scholar]
[38].Wei X., Decker J.M., Wang S., Hui H., Kappes J.C., Wu X., et al. Antibody neutralization and escape by HIV-1. Nature. 2003;422:307–312. doi: 10.1038/nature01470. [DOI] [PubMed] [Google Scholar]
[39].Land A., Braakman I. Folding of the human immunodeficiency virus type 1 envelope glycoprotein in the endoplasmic reticulum. Biochimie. 2001;83:783–790. doi: 10.1016/S0300-9084(01)01314-1. [DOI] [PubMed] [Google Scholar]
[40].Slater-Handshy T., Droll D.A., Fan X., Di Bisceglie A.M., Chambers T.J. HCV E2 glycoprotein: mutagenesis of N-linked glycosylation sites and its effects on E2 expression and processing. Virology. 2004;319:36–48. doi: 10.1016/j.virol.2003.10.008. [DOI] [PubMed] [Google Scholar]
[41].Meunier J.C., Fournillier A., Choukhi A., Cahour A., Cocquerel L., Dubuisson J., et al. Analysis of the glycosylation sites of hepatitis C virus (HCV) glycoprotein E1 and the influence of E1 glycans on the formation of the HCV glycoprotein complex. J. Gen. Virol. 1999;80:887–896. doi: 10.1099/0022-1317-80-4-887. [DOI] [PubMed] [Google Scholar]
[42].Wagner R., Wolff T., Herwig A., Pleschka S., Klenk H.D. Interdependence of hemagglutinin glycosylation and neuraminidase as regulators of influenza virus growth: a study by reverse genetics. J. Virol. 2000;74:6316–6323. doi: 10.1128/JVI.74.14.6316-6323.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
[43].Klenk H.D., Wagner R., Heuer D., Wolff T. Importance of hemagglutinin glycosylation for the biological functions of influenza virus. Virus Res. 2002;82:73–75. doi: 10.1016/S0168-1702(01)00389-6. [DOI] [PubMed] [Google Scholar]
[44].Baigent S.J., McCauley J.W. Glycosylation of haemagglutinin and stalk-length of neuraminidase combine to regulate the growth of avian influenza viruses in tissue culture. Virus Res. 2001;79:177–185. doi: 10.1016/S0168-1702(01)00272-6. [DOI] [PubMed] [Google Scholar]
[45].Tsuchiya E., Sugawara K., Hongo S., Matsuzaki Y., Muraki Y., Nakamura K. Role of overlapping glycosylation sequons in antigenic properties, intracellular transport and biological activities of influenza A/H2N2 virus haemagglutinin. J. Gen. Virol. 2002;83:3067–3074. doi: 10.1099/0022-1317-83-12-3067. [DOI] [PubMed] [Google Scholar]
[46].Tsuchiya E., Sugawara K., Hongo S., Matsuzaki Y., Muraki Y., Li Z.N., et al. Effect of addition of new oligosaccharide chains to the globular head of influenza A/H2N2 virus haemagglutinin on the intracellular transport and biological activities of the molecule. J. Gen. Virol. 2002;83:1137–1146. doi: 10.1099/0022-1317-83-5-1137. [DOI] [PubMed] [Google Scholar]
[47].Abe Y., Takashita E., Sugawara K., Matsuzaki Y., Muraki Y., Hongo S. Effect of the addition of oligosaccharides on the biological activities and antigenicity of influenza A/H3N2 virus hemagglutinin. J. Virol. 2004;78:9605–9611. doi: 10.1128/JVI.78.18.9605-9611.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
[48].Kaverin N.V., Rudneva I.A., Ilyushina N.A., Varich N.L., Lipatov A.S., Smirnov Y.A., et al. Structure of antigenic sites on the haemagglutinin molecule of H5 avian influenza virus and phenotypic variation of escape mutants. J. Gen. Virol. 2002;83:2497–2505. doi: 10.1099/0022-1317-83-10-2497. [DOI] [PubMed] [Google Scholar]
[49].Londrigan S.L., Turville S.G., Tate M.D., Deng Y.M., Brooks A.G., Reading P.C. N-linked Glycosylation Facilitates Sialic Acid-Independent Attachment and Entry of Influenza A Viruses into Cells Expressing DC-SIGN or L-SIGN. J. Virol. 2010;85:2990–3000. doi: 10.1128/JVI.01705-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
[50].Daniels R., Kurowski B., Johnson A.E., Hebert D.N. N-linked glycans direct the cotranslational folding pathway of influenza hemagglutinin. Mol. Cell. 2003;11:79–90. doi: 10.1016/S1097-2765(02)00821-3. [DOI] [PubMed] [Google Scholar]
[51].Skehel J.J., Wiley D.C. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Ann. Rev. Biochem. 2000;69:531–569. doi: 10.1146/annurev.biochem.69.1.531. [DOI] [PubMed] [Google Scholar]
[52].Vigerust D.J., Ulett K.B., Boyd K.L., Madsen J., Hawgood S., McCullers J.A. N-linked glycosylation attenuates H3N2 influenza viruses. J. Virol. 2007;81:8593–8600. doi: 10.1128/JVI.00769-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
[53].Job E.R., Deng Y.M., Tate M.D., Bottazzi B., Crouch E.C., Dean M.M., et al. Pandemic H1N1 influenza A viruses are resistant to the antiviral activities of innate immune proteins of the collectin and pentraxin superfamilies. J. Immunol. 2010;185:4284–4291. doi: 10.4049/jimmunol.1001613. [DOI] [PubMed] [Google Scholar]
[54].Deshpande K.L., Fried V.A., Ando M., Webster R.G. Glycosylation affects cleavage of an H5N2 influenza virus hemagglutinin and regulates virulence. Proc. Natl. Acad. Sci. USA. 1987;84:36–40. doi: 10.1073/pnas.84.1.36. [DOI] [PMC free article] [PubMed] [Google Scholar]
[55].Zambon M.C. Epidemiology and pathogenesis of influenza. J. Antimicrob. Chemother. 1999;44:3–9. doi: 10.1093/jac/44.suppl_2.3. [DOI] [PubMed] [Google Scholar]
[56].Das S.R., Puigbo P., Hensley S.E., Hurt D.E., Bennink J.R., Yewdell J.W. Glycosylation focuses sequence variation in the influenza A virus H1 hemagglutinin globular domain. PLoS Pathog. 2010;6:e1001211. doi: 10.1371/journal.ppat.1001211. [DOI] [PMC free article] [PubMed] [Google Scholar]
[57].Martin-Gallardo A., Fleischer E., Doyle S.A., Arumugham R., Collins P.L., Hildreth S.W., et al. Expression of the G glycoprotein gene of human respiratory syncytial virus in Salmonella typhimurium. J. Gen. Virol. 1993;74:453–458. doi: 10.1099/0022-1317-74-3-453. [DOI] [PubMed] [Google Scholar]
[58].Collins P.L., Mottet G. Oligomerization and posttranslational processing of glycoprotein G of human respiratory syncytial virus: altered O-glycosylation in the presence of brefeldin A. J. Gen. Virol. 1992;73:849–863. doi: 10.1099/0022-1317-73-4-849. [DOI] [PubMed] [Google Scholar]
[59].Aguilar H.C., Matreyek K.A., Filone C.M., Hashimi S.T., Levroney E.L., Negrete O.A., et al. N-glycans on Nipah virus fusion protein protect against neutralization but reduce membrane fusion and viral entry. J. Virol. 2006;80:4878–4889. doi: 10.1128/JVI.80.10.4878-4889.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
[60].Moll M., Kaufmann A., Maisner A. Influence of N-glycans on processing and biological activity of the nipah virus fusion protein. J. Virol. 2004;78:7274–7278. doi: 10.1128/JVI.78.13.7274-7278.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
[61].Bossart K.N., Crameri G., Dimitrov A.S., Mungall B.A., Feng Y.R., Patch J.R., et al. Receptor binding, fusion inhibition, and induction of crossreactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus. J. Virol. 2005;79:6690–6702. doi: 10.1128/JVI.79.11.6690-6702.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
[62].Oostra M., de Haan C.A., de Groot R.J., Rottier P.J. Glycosylation of the severe acute respiratory syndrome coronavirus triple-spanning membrane proteins 3a and M. J. Virol. 2006;80:2326–2336. doi: 10.1128/JVI.80.5.2326-2336.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
[63].Schowalter R.M., Smith S.E., Dutch R.E. Characterization of Human Metapneumovirus F Protein-Promoted Membrane Fusion: Critical Roles for Proteolytic Processing and Low pH. J. Virol. 2006;80:10931–10941. doi: 10.1128/JVI.01287-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
[64].Bowden T.A., Crispin M., Harvey D.J., Jones E.Y., Stuart D.I. Dimeric architecture of the Hendra virus attachment glycoprotein: evidence for a conserved mode of assembly. J. Virol. 2010;84:6208–6217. doi: 10.1128/JVI.00317-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
[65].Bowden T.A., Crispin M., Harvey D.J., Aricescu A.R., Grimes J.M., Jones E.Y., et al. Crystal structure and carbohydrate analysis of Nipah virus attachment glycoprotein: a template for antiviral and vaccine design. J. Virol. 2008;82:11628–11636. doi: 10.1128/JVI.01344-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
[66].Botarelli P., Houlden B.A., Haigwood N.L., Servis C., Montagna D., Abrignani S. N-glycosylation of HIV-gp120 may constrain recognition by T lymphocytes. J. Immunol. 1991;147:3128–3132. [PubMed] [Google Scholar]
[67].Zhu X., Borchers C., Bienstock R. J., Tomer K. B. Mass spectrometric characterization of the glycosylation pattern of HIV-gp120 expressed in CHO cells. Biochemistry. 2000;39:11194–204. doi: 10.1021/bi000432m. [DOI] [PubMed] [Google Scholar]
[68].Doores K.J., Bonomelli C., Harvey D.J., Vasiljevic S., Dwek R.A., Burton D.R., et al. Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proc. Natl. Acad. Sci. USA. 2010;107:13800–13805. doi: 10.1073/pnas.1006498107. [DOI] [PMC free article] [PubMed] [Google Scholar]
[69].Fenouillet E., Gluckman J.C., Bahraoui E. Role of N-linked glycans of envelope glycoproteins in infectivity of human immunodeficiency virus type 1. J. Virol. 1990;64:2841–2848. doi: 10.1128/jvi.64.6.2841-2848.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
[70].Montefiori D.C., Robinson W.E., Jr., Mitchell W.M. Role of protein N-glycosylation in pathogenesis of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA. 1988;85:9248–9252. doi: 10.1073/pnas.85.23.9248. [DOI] [PMC free article] [PubMed] [Google Scholar]
[71].Wyatt R., Kwong P.D., Desjardins E., Sweet R.W., Robinson J., Hendrickson W.A., et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature. 1998;393:705–711. doi: 10.1038/31514. [DOI] [PubMed] [Google Scholar]
[72].Poumbourios P., Maerz A.L., Drummer H.E. Functional evolution of the HIV-1 envelope glycoprotein 120 association site of glycoprotein 41. J. Biol. Chem. 2003;278:42149–42160. doi: 10.1074/jbc.M305223200. [DOI] [PubMed] [Google Scholar]
[73].Bunnik E.M., Euler Z., Welkers M.R., Boeser-Nunnink B.D., Grijsen M.L., Prins J.M., et al. Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level. Nat. Med. 2010;16:995–997. doi: 10.1038/nm.2203. [DOI] [PubMed] [Google Scholar]
[74].Chaillon A., Braibant M., Moreau T., Thenin S., Moreau A., Autran B., et al. The V1V2 domain and a N-linked glycosylation site in the V3 loop of the HIV-1 envelope glycoprotein modulate neutralization sensitivity to the human broadly neutralizing antibody 2G12. J. Virol. 2011;85:3642–3648. doi: 10.1128/JVI.02424-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
[75].Sanders R.W., Venturi M., Schiffner L., Kalyanaraman R., Katinger H., Lloyd K.O., et al. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J. Virol. 2002;76:7293–7305. doi: 10.1128/JVI.76.14.7293-7305.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
[76].Calarese D.A., Lee H.K., Huang C.Y., Best M.D., Astronomo R.D., Stanfield R.L., et al. Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12. Proc. Natl. Acad. Sci. USA. 2005;102:13372–13377. doi: 10.1073/pnas.0505763102. [DOI] [PMC free article] [PubMed] [Google Scholar]
[77].Calarese D.A., Scanlan C.N., Zwick M.B., Deechongkit S., Mimura Y., Kunert R., et al. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science. 2003;300:2065–2071. doi: 10.1126/science.1083182. [DOI] [PubMed] [Google Scholar]
[78].Lai J., Bernhard O.K., Turville S.G., Harman A.N., Wilkinson J., Cunningham A.L. Oligomerization of the macrophage mannose receptor enhances gp120-mediated binding of HIV-1. J. Biol. Chem. 2009;284:11027–110238. doi: 10.1074/jbc.M809698200. [DOI] [PMC free article] [PubMed] [Google Scholar]
[79].Frost S.D., Wrin T., Smith D.M., Kosakovsky Pond S.L., Liu Y., Paxinos E., et al., Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 enveloped [DOI] [PMC free article] [PubMed]
[80].Bonhomme C.J., Capul A.A., Lauron E.J., Bederka L.H., Knopp K.A., Buchmeier M.J. Glycosylation modulates arenavirus glycoprotein expression and function. Virology. 2011;409:223–233. doi: 10.1016/j.virol.2010.10.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
[81].Feldmann H., Nichol S.T., Klenk H.D., Peters C.J., Sanchez A. Characterization of filoviruses based on differences in structure and antigenicity of the virion glycoprotein. Virology. 1994;199:469–473. doi: 10.1006/viro.1994.1147. [DOI] [PubMed] [Google Scholar]
[82].Simmons G., Wool-Lewis R.J., Baribaud F., Netter R.C., Bates P. Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence. J. Virol. 2002;76:2518–2528. doi: 10.1128/jvi.76.5.2518-2528.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
[83].Dowling W., Thompson E., Badger C., Mellquist J.L., Garrison A.R., Smith J.M., et al. Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of ebola virus GP DNA vaccines. J. Virol. 2007;81:1821–1837. doi: 10.1128/JVI.02098-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
[84].Shi X., Elliott R.M. Analysis of N-linked glycosylation of hantaan virus glycoproteins and the role of oligosaccharide side chains in protein folding and intracellular trafficking. J. Virol. 2004;78:5414–5422. doi: 10.1128/JVI.78.10.5414-5422.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
[85].Zheng F., Ma L., Shao L., Wang G., Chen F., Zhang Y., et al. Defining the N-linked glycosylation site of Hantaan virus envelope glycoproteins essential for cell fusion. J. Microbiol. 2007;45:41–47. [PubMed] [Google Scholar]
[86].Robinson M.J., Sancho D., Slack E.C. LeibundGut-Landmann S., Reis e Sousa C., Myeloid C-type lectins in innate immunity. Nat. Immunol. 2006;7:1258–1265. doi: 10.1038/ni1417. [DOI] [PubMed] [Google Scholar]
[87].Weis W.I., Taylor M.E., Drickamer K. The C-type lectin superfamily in the immune system. Immunol. Rev. 1998;163:19–34. doi: 10.1111/j.1600-065X.1998.tb01185.x. [DOI] [PubMed] [Google Scholar]
[88].Cambi A., de Lange F., van Maarseveen N.M., Nijhuis M., Joosten B., van Dijk E.M., et al. Microdomains of the C-type lectin DC-SIGN are portals for virus entry into dendritic cells. J. Cell Biol. 2004;64:145–155. doi: 10.1083/jcb.200306112. [DOI] [PMC free article] [PubMed] [Google Scholar]
[89].Cambi A., Figdor C.G. Dual function of C-type lectin-like receptors in the immune system. Curr. Opin. Cell Biol. 2003;15:539–546. doi: 10.1016/j.ceb.2003.08.004. [DOI] [PubMed] [Google Scholar]
[90].Geijtenbeek T.B., van Vliet S.J., Engering A., Hart B.A., van Kooyk Y. Self- and nonself-recognition by C-type lectins on dendritic cells. Annu. Rev. Immunol. 2004;22:33–54. doi: 10.1146/annurev.immunol.22.012703.104558. [DOI] [PubMed] [Google Scholar]
[91].Rogers N.C., Slack E.C., Edwards A.D., Nolte M.A., Schulz O., Schweighoffer E., et al. Sykdependent cytokine induction by Dectin-1 reveals a novel pattern recognition pathway for C type lectins. Immunity. 2005;22:507–517. doi: 10.1016/j.immuni.2005.03.004. [DOI] [PubMed] [Google Scholar]
[92].Meyer-Wentrup F., Cambi A., Adema G.J., Figdor C.G. “Sweet talk”: closing in on C type lectin signaling. Immunity. 2005;22:399–400. doi: 10.1016/j.immuni.2005.04.001. [DOI] [PubMed] [Google Scholar]
[93].Upham J.P., Pickett D., Irimura T., Anders E.M., Reading P.C. Macrophage receptors for influenza A virus: role of the macrophage galactose-type lectin and mannose receptor in viral entry. J. Virol. 2010;84:3730–3737. doi: 10.1128/JVI.02148-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
[94].Reading P.C., Miller J.L., Anders E.M. Involvement of the mannose receptor in infection of macrophages by influenza virus. J. Virol. 2000;74:5190–5197. doi: 10.1128/JVI.74.11.5190-5197.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
[95].Nguyen D.G., Hildreth J.E. Involvement of macrophage mannose receptor in the binding and transmission of HIV by macrophages. Eur. J. Immunol. 2003;33:483–493. doi: 10.1002/immu.200310024. [DOI] [PubMed] [Google Scholar]
[96].Vigerust D.J., Egan B.S., Shepherd V.L. HIV-1 Nef mediates post-translational down-regulation and redistribution of the mannose receptor. J. Leukoc. Biol. 2005;77:522–534. doi: 10.1189/jlb.0804454. [DOI] [PubMed] [Google Scholar]
[97].Reiling N., Blumenthal A., Flad H.D., Ernst M., Ehlers S. Mycobacteria-induced TNF-alpha and IL-10 formation by human macrophages is differentially regulated at the level of mitogenactivated protein kinase activity. J. Immunol. 2001;167:3339–3345. doi: 10.4049/jimmunol.167.6.3339. [DOI] [PubMed] [Google Scholar]
[98].Bergman M., Del Prete G., van Kooyk Y., Appelmelk B. Helicobacter pylori phase variation, immune modulation and gastric autoimmunity. Nat. Rev. Microbiol. 2006;4:151–159. doi: 10.1038/nrmicro1344. [DOI] [PubMed] [Google Scholar]
[99].Cocquerel L., Voisset C., Dubuisson J. Hepatitis C virus entry: potential receptors and their biological functions. J. Gen. Virol. 2006;87:1075–1084. doi: 10.1099/vir.0.81646-0. [DOI] [PubMed] [Google Scholar]
[100].Lozach P.Y., Lortat-Jacob H., de Lacroix de Lavalette A., Staropoli I., Foung S., Amara A., et al. DC-SIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2. J. Biol. Chem. 2003;278:20358–20366. doi: 10.1074/jbc.M301284200. [DOI] [PubMed] [Google Scholar]
[101].Martina B.E., Koraka P., van den Doel P., Rimmelzwaan G.F., Haagmans B.L., Osterhaus A.D. DC-SIGN enhances infection of cells with glycosylated West Nile virus in vitro and virus replication in human dendritic cells induces production of IFN-alpha and TNF-alpha. Virus Res. 2008;135:64–71. doi: 10.1016/j.virusres.2008.02.008. [DOI] [PubMed] [Google Scholar]
[102].Hacker K., White L., de Silva A.M. N-linked glycans on dengue viruses grown in mammalian and insect cells. J. Gen. Virol. 2009;90:2097–2106. doi: 10.1099/vir.0.012120-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
[103].Davis C.W., Mattei L.M., Nguyen H.Y., Ansarah-Sobrinho C., Doms R.W., Pierson T.C. The location of asparagine-linked glycans on West Nile virions controls their interactions with CD209 (DCSIGN) J. Biol. Chem. 2006;281:37183–37194. doi: 10.1074/jbc.M605429200. [DOI] [PubMed] [Google Scholar]
[104].Davis C.W., Nguyen H.Y., Hanna S.L., Sanchez M.D., Doms R.W., Pierson T.C. West Nile virus discriminates between DC-SIGN and DC-SIGNR for cellular attachment and infection. J. Virol. 2006;80:1290–1301. doi: 10.1128/JVI.80.3.1290-1301.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
[105].Lin G., Simmons G., Pohlmann S., Baribaud F., Ni H., Leslie G.J., et al. Differential N-linked glycosylation of human immunodeficiency virus and Ebola virus envelope glycoproteins modulates interactions with DC-SIGN and DC-SIGNR. J. Virol. 2003;77:1337–1346. doi: 10.1128/JVI.77.2.1337-1346.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
[106].Turville S.G., Arthos J., Donald K.M., Lynch G., Naif H., Clark G., et al. HIV gp120 receptors on human dendritic cells. Blood. 2001;98:2482–2488. doi: 10.1182/blood.V98.8.2482. [DOI] [PubMed] [Google Scholar]
[107].Liu Y., Liu H., Kim B.O., Gattone V.H., Li J., Nath A., et al. CD4-independent infection of astrocytes by human immunodeficiency virus type 1: requirement for the human mannose receptor. J. Virol. 2004;78:4120–4133. doi: 10.1128/JVI.78.8.4120-4133.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
[108].Gramberg T., Hofmann H., Moller P., Lalor P.F., Marzi A., Geier M., et al. LSECtin interacts with filovirus glycoproteins and the spike protein of SARS coronavirus. Virology. 2005;340:224–236. doi: 10.1016/j.virol.2005.06.026. [DOI] [PMC free article] [PubMed] [Google Scholar]
[109].Pipirou Z., Powlesland A.S., Steffen I., Pohlmann S., Taylor M.E., Drickamer K. Mouse LSECtin as a model for a human Ebola virus receptor. Glycobiology. 2011;21:806–812. doi: 10.1093/glycob/cwr008. [DOI] [PMC free article] [PubMed] [Google Scholar]
[110].Li Y., Hao B., Kuai X., Xing G., Yang J., Chen J., et al. C-type lectin LSECtin interacts with DCSIGNR and is involved in hepatitis C virus binding. Mol. Cell. Biochem. 2009;327:183–190. doi: 10.1007/s11010-009-0056-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
[111].Francois K.O., Balzarini J., Potential of carbohydrate-binding agents as therapeutics against enveloped viruses, Med. Res. Rev., 2010, 31 [DOI] [PMC free article] [PubMed]
[112].Witvrouw M., Fikkert V., Hantson A., Pannecouque C., O’Keefe B.R., McMahon J., et al. Resistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A. J. Virol. 2005;79:7777–7784. doi: 10.1128/JVI.79.12.7777-7784.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
[113].Williams D.C., Jr., Lee J.Y., Cai M., Bewley C.A., Clore G.M. Crystal structures of the HIV-1 inhibitory cyanobacterial protein MVL free and bound to Man3GlcNAc2: structural basis for specificity and high-affinity binding to the core pentasaccharide from n-linked oligomannoside. J. Biol. Chem. 2005;280:29269–29276. doi: 10.1074/jbc.M504642200. [DOI] [PubMed] [Google Scholar]
[114].Balzarini J., Van Herrewege Y., Vermeire K., Vanham G., Schols D. Carbohydrate-binding agents efficiently prevent dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN)-directed HIV-1 transmission to T lymphocytes. Mol. Pharmacol. 2007;71:3–11. doi: 10.1124/mol.106.030155. [DOI] [PubMed] [Google Scholar]
[115].O’Keefe B.R., Smee D.F., Turpin J.A., Saucedo C.J., Gustafson K.R., Mori T., et al. Potent antiinfluenza activity of cyanovirin-N and interactions with viral hemagglutinin. Antimicrob. Agents Chemother. 2003;47:2518–2525. doi: 10.1128/AAC.47.8.2518-2525.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
[116].Balzarini J. Carbohydrate-binding agents: a potential future cornerstone for the chemotherapy of enveloped viruses? Antivir. Chem. Chemother. 2007;18:1–11. doi: 10.1177/095632020701800101. [DOI] [PubMed] [Google Scholar]
[117].Bertaux C., Daelemans D., Meertens L., Cormier E.G., Reinus J.F., Peumans W.J., et al. Entry of hepatitis C virus and human immunodeficiency virus is selectively inhibited by carbohydrate-binding agents but not by polyanions. Virology. 2007;36:40–50. doi: 10.1016/j.virol.2007.04.008. [DOI] [PubMed] [Google Scholar]
[118].Micewicz E.D., Cole A.L., Jung C.L., Luong H., Phillips M.L., Pratikhya P., et al. Grifonin-1: a small HIV-1 entry inhibitor derived from the algal lectin, Griffithsin. PLoS One. 2010;5:e14360. doi: 10.1371/journal.pone.0014360. [DOI] [PMC free article] [PubMed] [Google Scholar]
[119].Romanelli F., Smith K.M., Hoven A.D. Chloroquine and hydroxychloroquine as inhibitors of human immunodeficiency virus (HIV-1) activity. Curr. Pharm. Des. 2004;10:2643–2648. doi: 10.2174/1381612043383791. [DOI] [PubMed] [Google Scholar]
[120].Boelaert J.R., Sperber K., Piette J. Chloroquine exerts an additive in vitro anti-HIV type 1 effect when associated with didanosine and hydroxyurea. AIDS Res. Hum. Retroviruses. 1999;15:1241–7124. doi: 10.1089/088922299310133. [DOI] [PubMed] [Google Scholar]
[121].Sperber K., Louie M., Kraus T., Proner J., Sapira E., Lin S., et al. Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1. Clin. Ther. 1995;17:622–636. doi: 10.1016/0149-2918(95)80039-5. [DOI] [PubMed] [Google Scholar]
[122].Paton N.I., Aboulhab J. Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks. HIV Med. 2005;6:13–20. doi: 10.1111/j.1468-1293.2005.00259.x. [DOI] [PubMed] [Google Scholar]
[123].Naarding M.A., Baan E., Pollakis G., Paxton W.A. Effect of chloroquine on reducing HIV-1 replication in vitro and the DC-SIGN mediated transfer of virus to CD4+ T-lymphocytes. Retrovirology. 2007;4:6. doi: 10.1186/1742-4690-4-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
[124].Vincent M.J., Bergeron E., Benjannet S., Erickson B.R., Rollin P.E., Ksiazek T.G., et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol. J. 2005;2:69. doi: 10.1186/1743-422X-2-69. [DOI] [PMC free article] [PubMed] [Google Scholar]
[125].De Clercq E. Potential antivirals and antiviral strategies against SARS coronavirus infections. Expert Rev. Anti Infect. Ther. 2006;4:291–302. doi: 10.1586/14787210.4.2.291. [DOI] [PMC free article] [PubMed] [Google Scholar]
[126].Keyaerts E., Vijgen L., Maes P., Neyts J., Van Ranst M. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem. Biophys. Res. Commun. 2004;323:264–268. doi: 10.1016/j.bbrc.2004.08.085. [DOI] [PMC free article] [PubMed] [Google Scholar]
[127].Di Trani L., Savarino A., Campitelli L., Norelli S., Puzelli S., D’Ostilio D., et al. Different pH requirements are associated with divergent inhibitory effects of chloroquine on human and avian influenza A viruses. Virol. J. 2007;4:39. doi: 10.1186/1743-422X-4-39. [DOI] [PMC free article] [PubMed] [Google Scholar]
[128].Ooi E.E., Chew J.S., Loh J.P., Chua R.C. In vitro inhibition of human influenza A virus replication by chloroquine. Virol. J. 2006;3:39. doi: 10.1186/1743-422X-3-39. [DOI] [PMC free article] [PubMed] [Google Scholar]
[129].Savarino A., Di Trani L., Donatelli I., Cauda R., Cassone A. New insights into the antiviral effects of chloroquine. Lancet Infect. Dis. 2006;6:67–69. doi: 10.1016/S1473-3099(06)70361-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
[130].Rolain J.M., Colson P., Raoult D. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int. J. Antimicrob. Agents. 2007;30:297–308. doi: 10.1016/j.ijantimicag.2007.05.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
[131].Vigerust D.J., McCullers J.A. Chloroquine is effective against influenza A virus in vitro but not in vivo. Influenza Other Respi Viruses. 2007;1:189–192. doi: 10.1111/j.1750-2659.2007.00027.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
[132].Fedson D.S. Confronting an influenza pandemic with inexpensive generic agents: can it be done? Lancet Infect. Dis. 2008;8:571–576. doi: 10.1016/S1473-3099(08)70070-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
[133].Dwek R.A., Butters T.D., Platt F.M., Zitzmann N. Targeting glycosylation as a therapeutic approach. Nat. Rev. Drug Discov. 2002;1:65–75. doi: 10.1038/nrd708. [DOI] [PubMed] [Google Scholar]
[134].Chang J., Schul W., Butters T.D., Yip A., Liu B., Goh A., et al. Combination of alpha-glucosidase inhibitor and ribavirin for the treatment of dengue virus infection in vitro and in vivo. Antiviral Res. 2011;89:26–34. doi: 10.1016/j.antiviral.2010.11.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
[135].Chang J., Wang L., Ma D., Qu X., Guo H., Xu X., et al. Novel imino sugar derivatives demonstrate potent antiviral activity against flaviviruses. Antimicrob. Agents Chemother. 2009;53:1501–1508. doi: 10.1128/AAC.01457-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
[136].Vancova M., Nebesarova J., Grubhoffer L. Lectin-binding characteristics of a Lyme borreliosis spirochete Borrelia burgdorferi sensu stricto. Folia Microbiol., (Praha) 2005;50:229–238. doi: 10.1007/BF02931571. [DOI] [PubMed] [Google Scholar]
[137].Logan S.M., Hui J.P., Vinogradov E., Aubry A.J., Melanson J.E., Kelly J.F., et al. Identification of novel carbohydrate modifications on Campylobacter jejuni 11168 flagellin using metabolomics-based approaches. FEBS J. 2009;276:1014–1023. doi: 10.1111/j.1742-4658.2008.06840.x. [DOI] [PubMed] [Google Scholar]
[138].Appelmelk B.J., den Dunnen J., Driessen N.N., Ummels R., Pak M., Nigou J., et al. The mannose cap of mycobacterial lipoarabinomannan does not dominate the Mycobacterium-host interaction. Cell Microbiol. 2008;10:930–944. doi: 10.1111/j.1462-5822.2007.01097.x. [DOI] [PubMed] [Google Scholar]
[139].Twine S.M., Paul C.J., Vinogradov E., McNally D.J., Brisson J.R., Mullen J.A., et al. Flagellar glycosylation in Clostridium botulinum. FEBS J. 2008;275:4428–4444. doi: 10.1111/j.1742-4658.2008.06589.x. [DOI] [PubMed] [Google Scholar]
[140].Romanova J., Katinger D., Ferko B., Voglauer R., Mochalova L., Bovin N., et al. Distinct host range of influenza H3N2 virus isolates in Vero and MDCK cells is determined by cell specific glycosylation pattern. Virology. 2003;307:90–97. doi: 10.1016/S0042-6822(02)00064-8. [DOI] [PubMed] [Google Scholar]
[141].Wright K.E., Spiro R.C., Burns J.W., Buchmeier M.J. Post-translational processing of the glycoproteins of lymphocytic choriomeningitis virus. Virology. 1990;177:175–183. doi: 10.1016/0042-6822(90)90471-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
[142].Branco L.M., Garry R.F. Characterization of the Lassa virus GP1 ectodomain shedding: implications for improved diagnostic platforms. Virol. J. 2009;6:147. doi: 10.1186/1743-422X-6-147. [DOI] [PMC free article] [PubMed] [Google Scholar]
[143].Martinez I., Melero J.A. Binding of human respiratory syncytial virus to cells: implication of sulfated cell surface proteoglycans. J. Gen. Virol. 2000;81:2715–2722. doi: 10.1099/0022-1317-81-11-2715. [DOI] [PubMed] [Google Scholar]
[144].Feinberg H., Castelli R., Drickamer K., Seeberger P.H., Weis W.I. Multiple modes of binding enhance the affinity of DC-SIGN for high mannose N-linked glycans found on viral glycoproteins. J. Biol. Chem. 2007;282:4202–4209. doi: 10.1074/jbc.M609689200. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR1] [1].Witze E.S., Old W.M., Resing K.A., Ahn N.G. Mapping protein post-translational modifications with mass spectrometry. Nat. Methods. 2007;4:798–806. doi: 10.1038/nmeth1100. [DOI] [PubMed] [Google Scholar]

[CR2] [2].Spiro R.G. Protein glycosylation: nature, distribution, enzymatic formation, and disease implications of glycopeptide bonds. Glycobiology. 2002;12:43R–56R. doi: 10.1093/glycob/12.4.43R. [DOI] [PubMed] [Google Scholar]

[CR3] [3].Stepper J., Shastri S., Loo T.S., Preston J.C., Novak P., Man P., et al., Cysteine S-glycosylation, a new post-translational modification found in glycopeptide bacteriocins, FEBS letters, 585, 645–650 [DOI] [PubMed]

[CR4] [4].Furmanek A., Hofsteenge J. Protein C-mannosylation: facts and questions. Acta Biochim. Polon. 2000;47:781–789. [PubMed] [Google Scholar]

[CR5] [5].Falzarano D., Krokhin O., Van Domselaar G., Wolf K., Seebach J., Schnittler H.J., et al. Ebola sGP—the first viral glycoprotein shown to be C-mannosylated. Virology. 2007;368:83–90. doi: 10.1016/j.virol.2007.06.015. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR6] [6].Hartmann S., Hofsteenge J. Properdin, the positive regulator of complement, is highly C-mannosylated. J. Biol. Chem. 2000;275:28569–72854. doi: 10.1074/jbc.M001732200. [DOI] [PubMed] [Google Scholar]

[CR7] [7].Ristl R., Steiner K., Zarschler K., Zayni S., Messner P., Schaffer C., The s-layer glycome-adding to the sugar coat of bacteria, Int. J. Microbiol., 2011, pi 127870 [DOI] [PMC free article] [PubMed]

[CR8] [8].Apweiler R., Hermjakob H., Sharon N. On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database. Biochim. Biophys. Acta. 1999;1473:4–8. doi: 10.1016/s0304-4165(99)00165-8. [DOI] [PubMed] [Google Scholar]

[CR9] [9].Messner P. Prokaryotic glycoproteins: unexplored but important. J. Bacteriol. 2004;186:2517–2519. doi: 10.1128/JB.186.9.2517-2519.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR10] [10].Weerapana E., Imperiali B. Asparagine-linked protein glycosylation: from eukaryotic to prokaryotic systems. Glycobiology. 2006;16:91R–101R. doi: 10.1093/glycob/cwj099. [DOI] [PubMed] [Google Scholar]

[CR11] [11].Neuberger A. Carbohydrates in protein: The carbohydrate component of crystalline egg albumin. Biochem. J. 1938;32:1435–1451. doi: 10.1042/bj0321435. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR12] [12].Sleytr U. B., Thorne K. J. Chemical characterization of the regularly arranged surface layers of Clostridium thermosaccharolyticum and Clostridium thermohydrosulfuricum. J Bacteriol. 1976;126:377–83. doi: 10.1128/jb.126.1.377-383.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR13] [13].Sleytr U.B. Heterologous reattachment of regular arrays of glycoproteins on bacterial surfaces. Nature. 1975;257:400–402. doi: 10.1038/257400a0. [DOI] [PubMed] [Google Scholar]

[CR14] [14].Szymanski C.M., Logan S.M., Linton D., Wren B.W. Campylobacter—a tale of two protein glycosylation systems. Trends Microbiol. 2003;11:233–238. doi: 10.1016/S0966-842X(03)00079-9. [DOI] [PubMed] [Google Scholar]

[CR15] [15].Wacker M., Linton D., Hitchen P.G., Nita-Lazar M., Haslam S.M., North S.J., et al. N-linked glycosylation in Campylobacter jejuni and its functional transfer into E. coli. Science. 2002;298:1790–1793. doi: 10.1126/science.298.5599.1790. [DOI] [PubMed] [Google Scholar]

[CR16] [16].Abu-Qarn M., Eichler J. Protein N-glycosylation in Archaea: defining Haloferax volcanii genes involved in S-layer glycoprotein glycosylation. Mol. Microbiol. 2006;61:511–525. doi: 10.1111/j.1365-2958.2006.05252.x. [DOI] [PubMed] [Google Scholar]

[CR17] [17].Logan S.M. Flagellar glycosylation — a new component of the motility repertoire? Microbiology. 2006;152:1249–1262. doi: 10.1099/mic.0.28735-0. [DOI] [PubMed] [Google Scholar]

[CR18] [18].Castric P. pilO, a gene required for glycosylation of Pseudomonas aeruginosa 1244 pilin. Microbiology. 1995;141:1247–1254. doi: 10.1099/13500872-141-5-1247. [DOI] [PubMed] [Google Scholar]

[CR19] [19].Fletcher C.M., Coyne M.J., Villa O.F., Chatzidaki-Livanis M., Comstock L.E. A general O-glycosylation system important to the physiology of a major human intestinal symbiont. Cell. 2009;137:321–331. doi: 10.1016/j.cell.2009.02.041. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR20] [20].Coyne M.J., Reinap B., Lee M.M., Comstock L.E. Human symbionts use a host-like pathway for surface fucosylation. Science. 2005;307:1778–1781. doi: 10.1126/science.1106469. [DOI] [PubMed] [Google Scholar]

[CR21] [21].Power P.M., Seib K.L., Jennings M.P. Pilin glycosylation in Neisseria meningitidis occurs by a similar pathway to wzy-dependent O-antigen biosynthesis in Escherichia coli. Biochem. Biophys. Res. Commun. 2006;347:904–908. doi: 10.1016/j.bbrc.2006.06.182. [DOI] [PubMed] [Google Scholar]

[CR22] [22].Stimson E., Virji M., Makepeace K., Dell A., Morris H., Payne G., et al. Meningococcal pilin: a glycoprotein substituted with digalactosyl 2,4-diacetamido-2,4,6-trideoxyhexose. Mol. Microbiol. 1995;17:1201–1214. doi: 10.1111/j.1365-2958.1995.mmi_17061201.x. [DOI] [PubMed] [Google Scholar]

[CR23] [23].Virji M. Post-translational modifications of meningococcal pili. Identification of common substituents: glycans and alpha-glycerophosphate—a review. Gene. 1997;192:141–147. doi: 10.1016/S0378-1119(97)00082-6. [DOI] [PubMed] [Google Scholar]

[CR24] [24].Hegge F.T., Hitchen P.G., Aas F.E., Kristiansen H., Lovold C., Egge-Jacobsen W. Unique modifications with phosphocholine and phosphoethanolamine define alternate antigenic forms of Neisseria gonorrhoeae type IV pili. Proc. Natl. Acad. Sci. USA. 2004;101:10798–107803. doi: 10.1073/pnas.0402397101. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR25] [25].Castric P., Cassels F.J., Carlson R.W. Structural characterization of the Pseudomonas aeruginosa 1244 pilin glycan. J. Biol. Chem. 2001;276:26479–26485. doi: 10.1074/jbc.M102685200. [DOI] [PubMed] [Google Scholar]

[CR26] [26].Schirm M., Soo E.C., Aubry A.J., Austin J., Thibault P., Logan S.M. Structural, genetic and functional characterization of the flagellin glycosylation process in Helicobacter pylori. Mol. Microbiol. 2003;48:1579–1592. doi: 10.1046/j.1365-2958.2003.03527.x. [DOI] [PubMed] [Google Scholar]

[CR27] [27].McNally D.J., Aubry A.J., Hui J.P., Khieu N.H., Whitfield D., Ewing C.P., et al. Targeted metabolomics analysis of Campylobacter coli VC167 reveals legionaminic acid derivatives as novel flagellar glycans. J. Biol. Chem. 2007;282:14463–14475. doi: 10.1074/jbc.M611027200. [DOI] [PubMed] [Google Scholar]

[CR28] [28].Thibault P., Logan S.M., Kelly J.F., Brisson J.R., Ewing C.P., Trust T.J., et al. Identification of the carbohydrate moieties and glycosylation motifs in Campylobacter jejuni flagellin. J. Biol. Chem. 2001;276:34862–34870. doi: 10.1074/jbc.M104529200. [DOI] [PubMed] [Google Scholar]

[CR29] [29].Sambri V., Stefanelli C., Cevenini R. Detection of glycoproteins in Borrelia burgdorferi. Arch. Microbiol. 1992;157:205–208. doi: 10.1007/BF00245150. [DOI] [PubMed] [Google Scholar]

[CR30] [30].Swanson A.F., Kuo C.C. Binding of the glycan of the major outer membrane protein of Chlamydia trachomatis to HeLa cells. Infect. Immun. 1994;62:24–28. doi: 10.1128/iai.62.1.24-28.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR31] [31].Swanson A.F., Kuo C.C. The characterization of lectin-binding proteins of Chlamydia trachomatis as glycoproteins. Microb. Pathog. 1991;10:465–473. doi: 10.1016/0882-4010(91)90112-N. [DOI] [PubMed] [Google Scholar]

[CR32] [32].Swanson A.F., Kuo C.C. Evidence that the major outer membrane protein of Chlamydia trachomatis is glycosylated. Infect. Immun. 1991;59:2120–2125. doi: 10.1128/iai.59.6.2120-2125.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR33] [33].Lindenthal C., Elsinghorst E.A. Enterotoxigenic Escherichia coli TibA glycoprotein adheres to human intestine epithelial cells. Infect. Immun. 2001;69:52–57. doi: 10.1128/IAI.69.1.52-57.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR34] [34].Lindenthal C., Elsinghorst E.A. Identification of a glycoprotein produced by enterotoxigenic Escherichia coli. Infect. Immun. 1999;67:4084–4091. doi: 10.1128/iai.67.8.4084-4091.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR35] [35].Espitia C., Mancilla R. Identification, isolation and partial characterization of Mycobacterium tuberculosis glycoprotein antigens. Clin. Exp. Immunol. 1989;77:378–383. [PMC free article] [PubMed] [Google Scholar]

[CR36] [36].Mondotte J.A., Lozach P.Y., Amara A., Gamarnik A.V. Essential role of dengue virus envelope protein N glycosylation at asparagine-67 during viral propagation. J. Virol. 2007;81:7136–7148. doi: 10.1128/JVI.00116-07. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR37] [37].Korber B., Gaschen B., Yusim K., Thakallapally R., Kesmir C., Detours V. Evolutionary and immunological implications of contemporary HIV-1 variation. Br. Med. Bull. 2001;58:19–42. doi: 10.1093/bmb/58.1.19. [DOI] [PubMed] [Google Scholar]

[CR38] [38].Wei X., Decker J.M., Wang S., Hui H., Kappes J.C., Wu X., et al. Antibody neutralization and escape by HIV-1. Nature. 2003;422:307–312. doi: 10.1038/nature01470. [DOI] [PubMed] [Google Scholar]

[CR39] [39].Land A., Braakman I. Folding of the human immunodeficiency virus type 1 envelope glycoprotein in the endoplasmic reticulum. Biochimie. 2001;83:783–790. doi: 10.1016/S0300-9084(01)01314-1. [DOI] [PubMed] [Google Scholar]

[CR40] [40].Slater-Handshy T., Droll D.A., Fan X., Di Bisceglie A.M., Chambers T.J. HCV E2 glycoprotein: mutagenesis of N-linked glycosylation sites and its effects on E2 expression and processing. Virology. 2004;319:36–48. doi: 10.1016/j.virol.2003.10.008. [DOI] [PubMed] [Google Scholar]

[CR41] [41].Meunier J.C., Fournillier A., Choukhi A., Cahour A., Cocquerel L., Dubuisson J., et al. Analysis of the glycosylation sites of hepatitis C virus (HCV) glycoprotein E1 and the influence of E1 glycans on the formation of the HCV glycoprotein complex. J. Gen. Virol. 1999;80:887–896. doi: 10.1099/0022-1317-80-4-887. [DOI] [PubMed] [Google Scholar]

[CR42] [42].Wagner R., Wolff T., Herwig A., Pleschka S., Klenk H.D. Interdependence of hemagglutinin glycosylation and neuraminidase as regulators of influenza virus growth: a study by reverse genetics. J. Virol. 2000;74:6316–6323. doi: 10.1128/JVI.74.14.6316-6323.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR43] [43].Klenk H.D., Wagner R., Heuer D., Wolff T. Importance of hemagglutinin glycosylation for the biological functions of influenza virus. Virus Res. 2002;82:73–75. doi: 10.1016/S0168-1702(01)00389-6. [DOI] [PubMed] [Google Scholar]

[CR44] [44].Baigent S.J., McCauley J.W. Glycosylation of haemagglutinin and stalk-length of neuraminidase combine to regulate the growth of avian influenza viruses in tissue culture. Virus Res. 2001;79:177–185. doi: 10.1016/S0168-1702(01)00272-6. [DOI] [PubMed] [Google Scholar]

[CR45] [45].Tsuchiya E., Sugawara K., Hongo S., Matsuzaki Y., Muraki Y., Nakamura K. Role of overlapping glycosylation sequons in antigenic properties, intracellular transport and biological activities of influenza A/H2N2 virus haemagglutinin. J. Gen. Virol. 2002;83:3067–3074. doi: 10.1099/0022-1317-83-12-3067. [DOI] [PubMed] [Google Scholar]

[CR46] [46].Tsuchiya E., Sugawara K., Hongo S., Matsuzaki Y., Muraki Y., Li Z.N., et al. Effect of addition of new oligosaccharide chains to the globular head of influenza A/H2N2 virus haemagglutinin on the intracellular transport and biological activities of the molecule. J. Gen. Virol. 2002;83:1137–1146. doi: 10.1099/0022-1317-83-5-1137. [DOI] [PubMed] [Google Scholar]

[CR47] [47].Abe Y., Takashita E., Sugawara K., Matsuzaki Y., Muraki Y., Hongo S. Effect of the addition of oligosaccharides on the biological activities and antigenicity of influenza A/H3N2 virus hemagglutinin. J. Virol. 2004;78:9605–9611. doi: 10.1128/JVI.78.18.9605-9611.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR48] [48].Kaverin N.V., Rudneva I.A., Ilyushina N.A., Varich N.L., Lipatov A.S., Smirnov Y.A., et al. Structure of antigenic sites on the haemagglutinin molecule of H5 avian influenza virus and phenotypic variation of escape mutants. J. Gen. Virol. 2002;83:2497–2505. doi: 10.1099/0022-1317-83-10-2497. [DOI] [PubMed] [Google Scholar]

[CR49] [49].Londrigan S.L., Turville S.G., Tate M.D., Deng Y.M., Brooks A.G., Reading P.C. N-linked Glycosylation Facilitates Sialic Acid-Independent Attachment and Entry of Influenza A Viruses into Cells Expressing DC-SIGN or L-SIGN. J. Virol. 2010;85:2990–3000. doi: 10.1128/JVI.01705-10. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR50] [50].Daniels R., Kurowski B., Johnson A.E., Hebert D.N. N-linked glycans direct the cotranslational folding pathway of influenza hemagglutinin. Mol. Cell. 2003;11:79–90. doi: 10.1016/S1097-2765(02)00821-3. [DOI] [PubMed] [Google Scholar]

[CR51] [51].Skehel J.J., Wiley D.C. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Ann. Rev. Biochem. 2000;69:531–569. doi: 10.1146/annurev.biochem.69.1.531. [DOI] [PubMed] [Google Scholar]

[CR52] [52].Vigerust D.J., Ulett K.B., Boyd K.L., Madsen J., Hawgood S., McCullers J.A. N-linked glycosylation attenuates H3N2 influenza viruses. J. Virol. 2007;81:8593–8600. doi: 10.1128/JVI.00769-07. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR53] [53].Job E.R., Deng Y.M., Tate M.D., Bottazzi B., Crouch E.C., Dean M.M., et al. Pandemic H1N1 influenza A viruses are resistant to the antiviral activities of innate immune proteins of the collectin and pentraxin superfamilies. J. Immunol. 2010;185:4284–4291. doi: 10.4049/jimmunol.1001613. [DOI] [PubMed] [Google Scholar]

[CR54] [54].Deshpande K.L., Fried V.A., Ando M., Webster R.G. Glycosylation affects cleavage of an H5N2 influenza virus hemagglutinin and regulates virulence. Proc. Natl. Acad. Sci. USA. 1987;84:36–40. doi: 10.1073/pnas.84.1.36. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR55] [55].Zambon M.C. Epidemiology and pathogenesis of influenza. J. Antimicrob. Chemother. 1999;44:3–9. doi: 10.1093/jac/44.suppl_2.3. [DOI] [PubMed] [Google Scholar]

[CR56] [56].Das S.R., Puigbo P., Hensley S.E., Hurt D.E., Bennink J.R., Yewdell J.W. Glycosylation focuses sequence variation in the influenza A virus H1 hemagglutinin globular domain. PLoS Pathog. 2010;6:e1001211. doi: 10.1371/journal.ppat.1001211. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR57] [57].Martin-Gallardo A., Fleischer E., Doyle S.A., Arumugham R., Collins P.L., Hildreth S.W., et al. Expression of the G glycoprotein gene of human respiratory syncytial virus in Salmonella typhimurium. J. Gen. Virol. 1993;74:453–458. doi: 10.1099/0022-1317-74-3-453. [DOI] [PubMed] [Google Scholar]

[CR58] [58].Collins P.L., Mottet G. Oligomerization and posttranslational processing of glycoprotein G of human respiratory syncytial virus: altered O-glycosylation in the presence of brefeldin A. J. Gen. Virol. 1992;73:849–863. doi: 10.1099/0022-1317-73-4-849. [DOI] [PubMed] [Google Scholar]

[CR59] [59].Aguilar H.C., Matreyek K.A., Filone C.M., Hashimi S.T., Levroney E.L., Negrete O.A., et al. N-glycans on Nipah virus fusion protein protect against neutralization but reduce membrane fusion and viral entry. J. Virol. 2006;80:4878–4889. doi: 10.1128/JVI.80.10.4878-4889.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR60] [60].Moll M., Kaufmann A., Maisner A. Influence of N-glycans on processing and biological activity of the nipah virus fusion protein. J. Virol. 2004;78:7274–7278. doi: 10.1128/JVI.78.13.7274-7278.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR61] [61].Bossart K.N., Crameri G., Dimitrov A.S., Mungall B.A., Feng Y.R., Patch J.R., et al. Receptor binding, fusion inhibition, and induction of crossreactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus. J. Virol. 2005;79:6690–6702. doi: 10.1128/JVI.79.11.6690-6702.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR62] [62].Oostra M., de Haan C.A., de Groot R.J., Rottier P.J. Glycosylation of the severe acute respiratory syndrome coronavirus triple-spanning membrane proteins 3a and M. J. Virol. 2006;80:2326–2336. doi: 10.1128/JVI.80.5.2326-2336.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR63] [63].Schowalter R.M., Smith S.E., Dutch R.E. Characterization of Human Metapneumovirus F Protein-Promoted Membrane Fusion: Critical Roles for Proteolytic Processing and Low pH. J. Virol. 2006;80:10931–10941. doi: 10.1128/JVI.01287-06. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR64] [64].Bowden T.A., Crispin M., Harvey D.J., Jones E.Y., Stuart D.I. Dimeric architecture of the Hendra virus attachment glycoprotein: evidence for a conserved mode of assembly. J. Virol. 2010;84:6208–6217. doi: 10.1128/JVI.00317-10. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR65] [65].Bowden T.A., Crispin M., Harvey D.J., Aricescu A.R., Grimes J.M., Jones E.Y., et al. Crystal structure and carbohydrate analysis of Nipah virus attachment glycoprotein: a template for antiviral and vaccine design. J. Virol. 2008;82:11628–11636. doi: 10.1128/JVI.01344-08. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR66] [66].Botarelli P., Houlden B.A., Haigwood N.L., Servis C., Montagna D., Abrignani S. N-glycosylation of HIV-gp120 may constrain recognition by T lymphocytes. J. Immunol. 1991;147:3128–3132. [PubMed] [Google Scholar]

[CR67] [67].Zhu X., Borchers C., Bienstock R. J., Tomer K. B. Mass spectrometric characterization of the glycosylation pattern of HIV-gp120 expressed in CHO cells. Biochemistry. 2000;39:11194–204. doi: 10.1021/bi000432m. [DOI] [PubMed] [Google Scholar]

[CR68] [68].Doores K.J., Bonomelli C., Harvey D.J., Vasiljevic S., Dwek R.A., Burton D.R., et al. Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proc. Natl. Acad. Sci. USA. 2010;107:13800–13805. doi: 10.1073/pnas.1006498107. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR69] [69].Fenouillet E., Gluckman J.C., Bahraoui E. Role of N-linked glycans of envelope glycoproteins in infectivity of human immunodeficiency virus type 1. J. Virol. 1990;64:2841–2848. doi: 10.1128/jvi.64.6.2841-2848.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR70] [70].Montefiori D.C., Robinson W.E., Jr., Mitchell W.M. Role of protein N-glycosylation in pathogenesis of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA. 1988;85:9248–9252. doi: 10.1073/pnas.85.23.9248. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR71] [71].Wyatt R., Kwong P.D., Desjardins E., Sweet R.W., Robinson J., Hendrickson W.A., et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature. 1998;393:705–711. doi: 10.1038/31514. [DOI] [PubMed] [Google Scholar]

[CR72] [72].Poumbourios P., Maerz A.L., Drummer H.E. Functional evolution of the HIV-1 envelope glycoprotein 120 association site of glycoprotein 41. J. Biol. Chem. 2003;278:42149–42160. doi: 10.1074/jbc.M305223200. [DOI] [PubMed] [Google Scholar]

[CR73] [73].Bunnik E.M., Euler Z., Welkers M.R., Boeser-Nunnink B.D., Grijsen M.L., Prins J.M., et al. Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level. Nat. Med. 2010;16:995–997. doi: 10.1038/nm.2203. [DOI] [PubMed] [Google Scholar]

[CR74] [74].Chaillon A., Braibant M., Moreau T., Thenin S., Moreau A., Autran B., et al. The V1V2 domain and a N-linked glycosylation site in the V3 loop of the HIV-1 envelope glycoprotein modulate neutralization sensitivity to the human broadly neutralizing antibody 2G12. J. Virol. 2011;85:3642–3648. doi: 10.1128/JVI.02424-10. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR75] [75].Sanders R.W., Venturi M., Schiffner L., Kalyanaraman R., Katinger H., Lloyd K.O., et al. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J. Virol. 2002;76:7293–7305. doi: 10.1128/JVI.76.14.7293-7305.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR76] [76].Calarese D.A., Lee H.K., Huang C.Y., Best M.D., Astronomo R.D., Stanfield R.L., et al. Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12. Proc. Natl. Acad. Sci. USA. 2005;102:13372–13377. doi: 10.1073/pnas.0505763102. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR77] [77].Calarese D.A., Scanlan C.N., Zwick M.B., Deechongkit S., Mimura Y., Kunert R., et al. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science. 2003;300:2065–2071. doi: 10.1126/science.1083182. [DOI] [PubMed] [Google Scholar]

[CR78] [78].Lai J., Bernhard O.K., Turville S.G., Harman A.N., Wilkinson J., Cunningham A.L. Oligomerization of the macrophage mannose receptor enhances gp120-mediated binding of HIV-1. J. Biol. Chem. 2009;284:11027–110238. doi: 10.1074/jbc.M809698200. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR79] [79].Frost S.D., Wrin T., Smith D.M., Kosakovsky Pond S.L., Liu Y., Paxinos E., et al., Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 enveloped [DOI] [PMC free article] [PubMed]

[CR80] [80].Bonhomme C.J., Capul A.A., Lauron E.J., Bederka L.H., Knopp K.A., Buchmeier M.J. Glycosylation modulates arenavirus glycoprotein expression and function. Virology. 2011;409:223–233. doi: 10.1016/j.virol.2010.10.011. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR81] [81].Feldmann H., Nichol S.T., Klenk H.D., Peters C.J., Sanchez A. Characterization of filoviruses based on differences in structure and antigenicity of the virion glycoprotein. Virology. 1994;199:469–473. doi: 10.1006/viro.1994.1147. [DOI] [PubMed] [Google Scholar]

[CR82] [82].Simmons G., Wool-Lewis R.J., Baribaud F., Netter R.C., Bates P. Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence. J. Virol. 2002;76:2518–2528. doi: 10.1128/jvi.76.5.2518-2528.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR83] [83].Dowling W., Thompson E., Badger C., Mellquist J.L., Garrison A.R., Smith J.M., et al. Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of ebola virus GP DNA vaccines. J. Virol. 2007;81:1821–1837. doi: 10.1128/JVI.02098-06. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR84] [84].Shi X., Elliott R.M. Analysis of N-linked glycosylation of hantaan virus glycoproteins and the role of oligosaccharide side chains in protein folding and intracellular trafficking. J. Virol. 2004;78:5414–5422. doi: 10.1128/JVI.78.10.5414-5422.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR85] [85].Zheng F., Ma L., Shao L., Wang G., Chen F., Zhang Y., et al. Defining the N-linked glycosylation site of Hantaan virus envelope glycoproteins essential for cell fusion. J. Microbiol. 2007;45:41–47. [PubMed] [Google Scholar]

[CR86] [86].Robinson M.J., Sancho D., Slack E.C. LeibundGut-Landmann S., Reis e Sousa C., Myeloid C-type lectins in innate immunity. Nat. Immunol. 2006;7:1258–1265. doi: 10.1038/ni1417. [DOI] [PubMed] [Google Scholar]

[CR87] [87].Weis W.I., Taylor M.E., Drickamer K. The C-type lectin superfamily in the immune system. Immunol. Rev. 1998;163:19–34. doi: 10.1111/j.1600-065X.1998.tb01185.x. [DOI] [PubMed] [Google Scholar]

[CR88] [88].Cambi A., de Lange F., van Maarseveen N.M., Nijhuis M., Joosten B., van Dijk E.M., et al. Microdomains of the C-type lectin DC-SIGN are portals for virus entry into dendritic cells. J. Cell Biol. 2004;64:145–155. doi: 10.1083/jcb.200306112. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR89] [89].Cambi A., Figdor C.G. Dual function of C-type lectin-like receptors in the immune system. Curr. Opin. Cell Biol. 2003;15:539–546. doi: 10.1016/j.ceb.2003.08.004. [DOI] [PubMed] [Google Scholar]

[CR90] [90].Geijtenbeek T.B., van Vliet S.J., Engering A., Hart B.A., van Kooyk Y. Self- and nonself-recognition by C-type lectins on dendritic cells. Annu. Rev. Immunol. 2004;22:33–54. doi: 10.1146/annurev.immunol.22.012703.104558. [DOI] [PubMed] [Google Scholar]

[CR91] [91].Rogers N.C., Slack E.C., Edwards A.D., Nolte M.A., Schulz O., Schweighoffer E., et al. Sykdependent cytokine induction by Dectin-1 reveals a novel pattern recognition pathway for C type lectins. Immunity. 2005;22:507–517. doi: 10.1016/j.immuni.2005.03.004. [DOI] [PubMed] [Google Scholar]

[CR92] [92].Meyer-Wentrup F., Cambi A., Adema G.J., Figdor C.G. “Sweet talk”: closing in on C type lectin signaling. Immunity. 2005;22:399–400. doi: 10.1016/j.immuni.2005.04.001. [DOI] [PubMed] [Google Scholar]

[CR93] [93].Upham J.P., Pickett D., Irimura T., Anders E.M., Reading P.C. Macrophage receptors for influenza A virus: role of the macrophage galactose-type lectin and mannose receptor in viral entry. J. Virol. 2010;84:3730–3737. doi: 10.1128/JVI.02148-09. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR94] [94].Reading P.C., Miller J.L., Anders E.M. Involvement of the mannose receptor in infection of macrophages by influenza virus. J. Virol. 2000;74:5190–5197. doi: 10.1128/JVI.74.11.5190-5197.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR95] [95].Nguyen D.G., Hildreth J.E. Involvement of macrophage mannose receptor in the binding and transmission of HIV by macrophages. Eur. J. Immunol. 2003;33:483–493. doi: 10.1002/immu.200310024. [DOI] [PubMed] [Google Scholar]

[CR96] [96].Vigerust D.J., Egan B.S., Shepherd V.L. HIV-1 Nef mediates post-translational down-regulation and redistribution of the mannose receptor. J. Leukoc. Biol. 2005;77:522–534. doi: 10.1189/jlb.0804454. [DOI] [PubMed] [Google Scholar]

[CR97] [97].Reiling N., Blumenthal A., Flad H.D., Ernst M., Ehlers S. Mycobacteria-induced TNF-alpha and IL-10 formation by human macrophages is differentially regulated at the level of mitogenactivated protein kinase activity. J. Immunol. 2001;167:3339–3345. doi: 10.4049/jimmunol.167.6.3339. [DOI] [PubMed] [Google Scholar]

[CR98] [98].Bergman M., Del Prete G., van Kooyk Y., Appelmelk B. Helicobacter pylori phase variation, immune modulation and gastric autoimmunity. Nat. Rev. Microbiol. 2006;4:151–159. doi: 10.1038/nrmicro1344. [DOI] [PubMed] [Google Scholar]

[CR99] [99].Cocquerel L., Voisset C., Dubuisson J. Hepatitis C virus entry: potential receptors and their biological functions. J. Gen. Virol. 2006;87:1075–1084. doi: 10.1099/vir.0.81646-0. [DOI] [PubMed] [Google Scholar]

[CR100] [100].Lozach P.Y., Lortat-Jacob H., de Lacroix de Lavalette A., Staropoli I., Foung S., Amara A., et al. DC-SIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2. J. Biol. Chem. 2003;278:20358–20366. doi: 10.1074/jbc.M301284200. [DOI] [PubMed] [Google Scholar]

[CR101] [101].Martina B.E., Koraka P., van den Doel P., Rimmelzwaan G.F., Haagmans B.L., Osterhaus A.D. DC-SIGN enhances infection of cells with glycosylated West Nile virus in vitro and virus replication in human dendritic cells induces production of IFN-alpha and TNF-alpha. Virus Res. 2008;135:64–71. doi: 10.1016/j.virusres.2008.02.008. [DOI] [PubMed] [Google Scholar]

[CR102] [102].Hacker K., White L., de Silva A.M. N-linked glycans on dengue viruses grown in mammalian and insect cells. J. Gen. Virol. 2009;90:2097–2106. doi: 10.1099/vir.0.012120-0. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR103] [103].Davis C.W., Mattei L.M., Nguyen H.Y., Ansarah-Sobrinho C., Doms R.W., Pierson T.C. The location of asparagine-linked glycans on West Nile virions controls their interactions with CD209 (DCSIGN) J. Biol. Chem. 2006;281:37183–37194. doi: 10.1074/jbc.M605429200. [DOI] [PubMed] [Google Scholar]

[CR104] [104].Davis C.W., Nguyen H.Y., Hanna S.L., Sanchez M.D., Doms R.W., Pierson T.C. West Nile virus discriminates between DC-SIGN and DC-SIGNR for cellular attachment and infection. J. Virol. 2006;80:1290–1301. doi: 10.1128/JVI.80.3.1290-1301.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR105] [105].Lin G., Simmons G., Pohlmann S., Baribaud F., Ni H., Leslie G.J., et al. Differential N-linked glycosylation of human immunodeficiency virus and Ebola virus envelope glycoproteins modulates interactions with DC-SIGN and DC-SIGNR. J. Virol. 2003;77:1337–1346. doi: 10.1128/JVI.77.2.1337-1346.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR106] [106].Turville S.G., Arthos J., Donald K.M., Lynch G., Naif H., Clark G., et al. HIV gp120 receptors on human dendritic cells. Blood. 2001;98:2482–2488. doi: 10.1182/blood.V98.8.2482. [DOI] [PubMed] [Google Scholar]

[CR107] [107].Liu Y., Liu H., Kim B.O., Gattone V.H., Li J., Nath A., et al. CD4-independent infection of astrocytes by human immunodeficiency virus type 1: requirement for the human mannose receptor. J. Virol. 2004;78:4120–4133. doi: 10.1128/JVI.78.8.4120-4133.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR108] [108].Gramberg T., Hofmann H., Moller P., Lalor P.F., Marzi A., Geier M., et al. LSECtin interacts with filovirus glycoproteins and the spike protein of SARS coronavirus. Virology. 2005;340:224–236. doi: 10.1016/j.virol.2005.06.026. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR109] [109].Pipirou Z., Powlesland A.S., Steffen I., Pohlmann S., Taylor M.E., Drickamer K. Mouse LSECtin as a model for a human Ebola virus receptor. Glycobiology. 2011;21:806–812. doi: 10.1093/glycob/cwr008. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR110] [110].Li Y., Hao B., Kuai X., Xing G., Yang J., Chen J., et al. C-type lectin LSECtin interacts with DCSIGNR and is involved in hepatitis C virus binding. Mol. Cell. Biochem. 2009;327:183–190. doi: 10.1007/s11010-009-0056-y. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR111] [111].Francois K.O., Balzarini J., Potential of carbohydrate-binding agents as therapeutics against enveloped viruses, Med. Res. Rev., 2010, 31 [DOI] [PMC free article] [PubMed]

[CR112] [112].Witvrouw M., Fikkert V., Hantson A., Pannecouque C., O’Keefe B.R., McMahon J., et al. Resistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A. J. Virol. 2005;79:7777–7784. doi: 10.1128/JVI.79.12.7777-7784.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR113] [113].Williams D.C., Jr., Lee J.Y., Cai M., Bewley C.A., Clore G.M. Crystal structures of the HIV-1 inhibitory cyanobacterial protein MVL free and bound to Man3GlcNAc2: structural basis for specificity and high-affinity binding to the core pentasaccharide from n-linked oligomannoside. J. Biol. Chem. 2005;280:29269–29276. doi: 10.1074/jbc.M504642200. [DOI] [PubMed] [Google Scholar]

[CR114] [114].Balzarini J., Van Herrewege Y., Vermeire K., Vanham G., Schols D. Carbohydrate-binding agents efficiently prevent dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN)-directed HIV-1 transmission to T lymphocytes. Mol. Pharmacol. 2007;71:3–11. doi: 10.1124/mol.106.030155. [DOI] [PubMed] [Google Scholar]

[CR115] [115].O’Keefe B.R., Smee D.F., Turpin J.A., Saucedo C.J., Gustafson K.R., Mori T., et al. Potent antiinfluenza activity of cyanovirin-N and interactions with viral hemagglutinin. Antimicrob. Agents Chemother. 2003;47:2518–2525. doi: 10.1128/AAC.47.8.2518-2525.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR116] [116].Balzarini J. Carbohydrate-binding agents: a potential future cornerstone for the chemotherapy of enveloped viruses? Antivir. Chem. Chemother. 2007;18:1–11. doi: 10.1177/095632020701800101. [DOI] [PubMed] [Google Scholar]

[CR117] [117].Bertaux C., Daelemans D., Meertens L., Cormier E.G., Reinus J.F., Peumans W.J., et al. Entry of hepatitis C virus and human immunodeficiency virus is selectively inhibited by carbohydrate-binding agents but not by polyanions. Virology. 2007;36:40–50. doi: 10.1016/j.virol.2007.04.008. [DOI] [PubMed] [Google Scholar]

[CR118] [118].Micewicz E.D., Cole A.L., Jung C.L., Luong H., Phillips M.L., Pratikhya P., et al. Grifonin-1: a small HIV-1 entry inhibitor derived from the algal lectin, Griffithsin. PLoS One. 2010;5:e14360. doi: 10.1371/journal.pone.0014360. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR119] [119].Romanelli F., Smith K.M., Hoven A.D. Chloroquine and hydroxychloroquine as inhibitors of human immunodeficiency virus (HIV-1) activity. Curr. Pharm. Des. 2004;10:2643–2648. doi: 10.2174/1381612043383791. [DOI] [PubMed] [Google Scholar]

[CR120] [120].Boelaert J.R., Sperber K., Piette J. Chloroquine exerts an additive in vitro anti-HIV type 1 effect when associated with didanosine and hydroxyurea. AIDS Res. Hum. Retroviruses. 1999;15:1241–7124. doi: 10.1089/088922299310133. [DOI] [PubMed] [Google Scholar]

[CR121] [121].Sperber K., Louie M., Kraus T., Proner J., Sapira E., Lin S., et al. Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1. Clin. Ther. 1995;17:622–636. doi: 10.1016/0149-2918(95)80039-5. [DOI] [PubMed] [Google Scholar]

[CR122] [122].Paton N.I., Aboulhab J. Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks. HIV Med. 2005;6:13–20. doi: 10.1111/j.1468-1293.2005.00259.x. [DOI] [PubMed] [Google Scholar]

[CR123] [123].Naarding M.A., Baan E., Pollakis G., Paxton W.A. Effect of chloroquine on reducing HIV-1 replication in vitro and the DC-SIGN mediated transfer of virus to CD4+ T-lymphocytes. Retrovirology. 2007;4:6. doi: 10.1186/1742-4690-4-6. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR124] [124].Vincent M.J., Bergeron E., Benjannet S., Erickson B.R., Rollin P.E., Ksiazek T.G., et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol. J. 2005;2:69. doi: 10.1186/1743-422X-2-69. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR125] [125].De Clercq E. Potential antivirals and antiviral strategies against SARS coronavirus infections. Expert Rev. Anti Infect. Ther. 2006;4:291–302. doi: 10.1586/14787210.4.2.291. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR126] [126].Keyaerts E., Vijgen L., Maes P., Neyts J., Van Ranst M. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem. Biophys. Res. Commun. 2004;323:264–268. doi: 10.1016/j.bbrc.2004.08.085. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR127] [127].Di Trani L., Savarino A., Campitelli L., Norelli S., Puzelli S., D’Ostilio D., et al. Different pH requirements are associated with divergent inhibitory effects of chloroquine on human and avian influenza A viruses. Virol. J. 2007;4:39. doi: 10.1186/1743-422X-4-39. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR128] [128].Ooi E.E., Chew J.S., Loh J.P., Chua R.C. In vitro inhibition of human influenza A virus replication by chloroquine. Virol. J. 2006;3:39. doi: 10.1186/1743-422X-3-39. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR129] [129].Savarino A., Di Trani L., Donatelli I., Cauda R., Cassone A. New insights into the antiviral effects of chloroquine. Lancet Infect. Dis. 2006;6:67–69. doi: 10.1016/S1473-3099(06)70361-9. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR130] [130].Rolain J.M., Colson P., Raoult D. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int. J. Antimicrob. Agents. 2007;30:297–308. doi: 10.1016/j.ijantimicag.2007.05.015. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR131] [131].Vigerust D.J., McCullers J.A. Chloroquine is effective against influenza A virus in vitro but not in vivo. Influenza Other Respi Viruses. 2007;1:189–192. doi: 10.1111/j.1750-2659.2007.00027.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR132] [132].Fedson D.S. Confronting an influenza pandemic with inexpensive generic agents: can it be done? Lancet Infect. Dis. 2008;8:571–576. doi: 10.1016/S1473-3099(08)70070-7. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR133] [133].Dwek R.A., Butters T.D., Platt F.M., Zitzmann N. Targeting glycosylation as a therapeutic approach. Nat. Rev. Drug Discov. 2002;1:65–75. doi: 10.1038/nrd708. [DOI] [PubMed] [Google Scholar]

[CR134] [134].Chang J., Schul W., Butters T.D., Yip A., Liu B., Goh A., et al. Combination of alpha-glucosidase inhibitor and ribavirin for the treatment of dengue virus infection in vitro and in vivo. Antiviral Res. 2011;89:26–34. doi: 10.1016/j.antiviral.2010.11.002. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR135] [135].Chang J., Wang L., Ma D., Qu X., Guo H., Xu X., et al. Novel imino sugar derivatives demonstrate potent antiviral activity against flaviviruses. Antimicrob. Agents Chemother. 2009;53:1501–1508. doi: 10.1128/AAC.01457-08. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR136] [136].Vancova M., Nebesarova J., Grubhoffer L. Lectin-binding characteristics of a Lyme borreliosis spirochete Borrelia burgdorferi sensu stricto. Folia Microbiol., (Praha) 2005;50:229–238. doi: 10.1007/BF02931571. [DOI] [PubMed] [Google Scholar]

[CR137] [137].Logan S.M., Hui J.P., Vinogradov E., Aubry A.J., Melanson J.E., Kelly J.F., et al. Identification of novel carbohydrate modifications on Campylobacter jejuni 11168 flagellin using metabolomics-based approaches. FEBS J. 2009;276:1014–1023. doi: 10.1111/j.1742-4658.2008.06840.x. [DOI] [PubMed] [Google Scholar]

[CR138] [138].Appelmelk B.J., den Dunnen J., Driessen N.N., Ummels R., Pak M., Nigou J., et al. The mannose cap of mycobacterial lipoarabinomannan does not dominate the Mycobacterium-host interaction. Cell Microbiol. 2008;10:930–944. doi: 10.1111/j.1462-5822.2007.01097.x. [DOI] [PubMed] [Google Scholar]

[CR139] [139].Twine S.M., Paul C.J., Vinogradov E., McNally D.J., Brisson J.R., Mullen J.A., et al. Flagellar glycosylation in Clostridium botulinum. FEBS J. 2008;275:4428–4444. doi: 10.1111/j.1742-4658.2008.06589.x. [DOI] [PubMed] [Google Scholar]

[CR140] [140].Romanova J., Katinger D., Ferko B., Voglauer R., Mochalova L., Bovin N., et al. Distinct host range of influenza H3N2 virus isolates in Vero and MDCK cells is determined by cell specific glycosylation pattern. Virology. 2003;307:90–97. doi: 10.1016/S0042-6822(02)00064-8. [DOI] [PubMed] [Google Scholar]

[CR141] [141].Wright K.E., Spiro R.C., Burns J.W., Buchmeier M.J. Post-translational processing of the glycoproteins of lymphocytic choriomeningitis virus. Virology. 1990;177:175–183. doi: 10.1016/0042-6822(90)90471-3. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR142] [142].Branco L.M., Garry R.F. Characterization of the Lassa virus GP1 ectodomain shedding: implications for improved diagnostic platforms. Virol. J. 2009;6:147. doi: 10.1186/1743-422X-6-147. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR143] [143].Martinez I., Melero J.A. Binding of human respiratory syncytial virus to cells: implication of sulfated cell surface proteoglycans. J. Gen. Virol. 2000;81:2715–2722. doi: 10.1099/0022-1317-81-11-2715. [DOI] [PubMed] [Google Scholar]

[CR144] [144].Feinberg H., Castelli R., Drickamer K., Seeberger P.H., Weis W.I. Multiple modes of binding enhance the affinity of DC-SIGN for high mannose N-linked glycans found on viral glycoproteins. J. Biol. Chem. 2007;282:4202–4209. doi: 10.1074/jbc.M609689200. [DOI] [PMC free article] [PubMed] [Google Scholar]

PERMALINK

Protein glycosylation in infectious disease pathobiology and treatment

David J Vigerust

Abstract

References

ACTIONS

PERMALINK

RESOURCES

Cite

Add to Collections

PERMALINK

Protein glycosylation in infectious disease pathobiology and treatment

David J Vigerust

Abstract

References

ACTIONS

PERMALINK

RESOURCES

Similar articles

Cited by other articles

Links to NCBI Databases